HC Wainwright Reduces Earnings Estimates for Atossa Genetics

Atossa Genetics Inc. (NASDAQ:ATOS) – Equities researchers at HC Wainwright cut their Q1 2026 EPS estimates for shares of Atossa Genetics in a report released on Thursday, March 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.34) for the quarter, down from their previous estimate of ($1.20). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.03) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at ($0.20) EPS.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Ascendiant Capital Markets raised their target price on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Atossa Genetics presently has an average rating of “Hold” and an average price target of $68.33.

Atossa Genetics Stock Up 11.7%

ATOS opened at $5.26 on Monday. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The business has a fifty day simple moving average of $5.54 and a 200-day simple moving average of $9.80. The firm has a market cap of $45.29 million, a P/E ratio of -1.46 and a beta of 1.42.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP increased its position in shares of Atossa Genetics by 509.0% during the third quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after acquiring an additional 259,725 shares during the period. JPMorgan Chase & Co. boosted its holdings in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the period. &PARTNERS acquired a new position in Atossa Genetics during the 4th quarter worth $25,000. Bank of America Corp DE grew its stake in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.